Lifecore Biomedical Inc

Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Maria, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q3 2024

Earnings data Q2 2024

Earnings data Q1 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q3 2025

Lifecore Biomedical explores strategic alternatives and strengthens supply agreements

Lifecore Biomedical's Q3 2023 performance was steady, with strategic strengths in supply agreements and expertise in pharmaceutical injectable-grade HA. However, challenges from timing shifts and inflationary pressures were evident. The company anticipates increased revenue-generating capacity and sees opportunities in expanded supply agreements.

Lifecore Biomedical explores strategic alternatives amidst revenue decline and debt challenges

Lifecore Biomedical's Q2 2023 performance reflects revenue decline, lower gross profit, and challenges from heavy debt burden. The company's strategic review process, led by Morgan Stanley, aims to maximize shareholder value through potential sales or financing transactions. Despite uncertainties leading to the withdrawal of fiscal outlook, Lifecore maintains a proactive stance in addressing operational and financial challenges.

Lifecore Biomedical strengthens partnerships and capacity for future growth

Lifecore Biomedical navigated challenges in Q3 2023 with a focus on strategic partnerships, capacity investments, and a vision for significant revenue growth in the future.
Despite a decrease in financial metrics for the quarter, Lifecore's strengths in CDMO services, development portfolio, and agreements with Alcon position it for long-term success.
Opportunities for growth lie in expanding HA raw material manufacturing, doubling capacity, and leveraging industry trends for revenue expansion in the coming years.

Lifecore Biomedical reports revenue growth and strategic investments for growth

Lifecore Biomedical's Q4 2023 performance showed revenue growth and strategic investments in capacity expansion. While facing challenges in maintaining gross profit margins, the company's focus on CDMO services and development projects presents growth opportunities. Uncertainties surrounding fiscal year 2024 guidance indicate ongoing strategic review processes and potential impacts on future performance.

Lifecore Biomedical reports robust fiscal 2024 performance amidst flat 2025 outlook

Lifecore Biomedical demonstrated strong financial performance in fiscal 2024 with notable revenue and profit increases. While challenges like divestitures impacted the company, strategic measures such as workforce reduction and growth strategies position Lifecore for future success. Opportunities lie in the potential for continued financial growth and revenue generation through targeted strategies.

Lifecore Biomedical reports revenue growth amidst challenges, eyes sustainable growth

Lifecore Biomedical Inc showcased revenue growth and operational improvements in Q1 2025, despite facing a net loss. The company's focus on customer acquisition, expansion, and financial stability presents opportunities for future growth and enhanced performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. It focuses on selling products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic and other markets. The company was founded by Otto Sartorius in 1965 and is headquartered in Chaska, MN.

CHASKA, Minn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (Nasdaq: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), reported results for the fiscal 2023 fourth quarter and full year ended May 28, 2023.

Lifecore Biomedical Reports Fourth Quarter and Full Fiscal Year 2023 Results

CHASKA, Minn., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will host a conference call to discuss fiscal 2023 fourth quarter financial results. The live webcast can be accessed via Lifecore's website on the Investor Events & Presentations page. The webcast will be available for 30 days.

Lifecore Biomedical Sets Fourth Quarter 2023 Earnings Conference Call for August 31, 2023 at 7:30 a.m. CT

QIAGEN

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Qiagen (QGEN) or Lifecore Biomedical (LFCR). But which of these two stocks is more attractive to value investors?

QGEN vs. LFCR: Which Stock Is the Better Value Option?

Lifecore Biomedical, Inc. is running a sale process. Laughing Water Capital believes upside of 150% is possible over the next three months. The Company's assets are highly strategic, and thus attractive to multiple potential buyers. Capacity will be doubling in the near term, and buyers have a track record of paying up for pending capacity in this industry.

Lifecore: Highly Skewed Special Situation

Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Q3 2023 Earnings Conference Call June 1, 2023 8:30 AM ET Company Participants Jim Hall - President John Morberg - CFO Conference Call Participants Operator Good morning, and thank you for joining us today to discuss Lifecore Biomedical's Third Quarter Fiscal 2023 Earnings Results. Hosting the call today from the company are Jim Hall, President and Chief Executive Officer; and John Morberg, Chief Financial Officer.

Lifecore Biomedical, Inc. (LFCR) Q3 2023 Earnings Call Transcript

Going concern qualification is removed as a result of the $150 million new financing transaction announced last week Going concern qualification is removed as a result of the $150 million new financing transaction announced last week

Lifecore Biomedical Reports Third Quarter Fiscal Year 2023 Results

Lifecore Biomedical jumped 50% yesterday after the company finally dispelled the previous going concern risk. Despite the share price jump, there are two other short-term catalysts here that could propel the share price much higher. One of those catalysts is a company sale.

Lifecore Biomedical: Potential Company Sale

Shares of Lifecore Biomedical on Monday climbed 19% to $6.40 in after-hours trading after the company said it secured a new $150 million financing agreement with its long-term customer Alcon.

Lifecore Biomedical stock climbs 19% on $150 million refinancing deal

New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to replace existing term loan New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to replace existing term loan

Lifecore Biomedical Enters into $150.0 Million in New Financing, Repays its Outstanding Term Loans and Signs New Supply Agreement to Expand HA Fermentation Capacity with Existing Long-Term Customer

CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will host a conference call to discuss fiscal 2023 third quarter financial results. The live webcast can be accessed via Lifecore's website on the Investor Events & Presentations page. The webcast will be available for 30 days.

Lifecore Biomedical Sets Third Quarter 2023 Earnings Conference Call for June 1, 2023 at 7:30 a.m. CT

Lifecore: Extraordinary Upside Likely Despite Bankruptcy Concerns.

Lifecore: Extraordinary Upside Likely Despite Bankruptcy Concerns

CHASKA, Minn., April 06, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has completed the sale of all of its Curation Foods' assets related to the O Olive Oil and Vinegar® business (“O Olive”) for $6.23 million, subject to certain customary post-closing adjustments.

Lifecore Biomedical Announces Sale of Curation Foods' O Olive Oil and Vinegar® Business

Hut 8 Mining Corp

Oatly

Penny stocks to buy according to 3 analysts. The post 3 Penny Stocks To Buy According To Analysts, Targets Up To 170% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Buy According To Analysts, Targets Up To 170%

Penny stocks to buy according to 3 analysts. The post 3 Penny Stocks To Buy According To Analysts, Targets Up To %170 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Buy According To Analysts, Targets Up To %170

Allarity Therapeutics

Loyalty Ventures

Use these tips for finding high potential penny stocks The post High-Potential: A Short Guide to Penny Stock Investing appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

High-Potential: A Short Guide to Penny Stock Investing

Provides $10 million upfront cash commitment to Lifecore for infrastructure preparation and production capacity preparation

Lifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship

CHASKA, Minn., March 16, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the Board of Directors of the Company (the “Board”) intends to initiate a process to evaluate the Company's potential strategic alternatives to maximize value for stockholders. As part of the process, the Board intends to consider a full range of strategic alternatives, which could include a sale of the Company, potential debt or equity financing transactions, or other possible strategic transactions.

Lifecore Biomedical Announces Intent to Explore Strategic Alternatives

Company Announces Intention to Explore Strategic Alternatives Signs Term Sheet with Key Customer to Materially Expand Commercial Relationship Expands Development Pipeline from 24 to 25 Active Projects as of Fiscal Second Quarter-end Subsequently Transitioned Three Projects to Commercialization with FDA Approval in Fiscal Third Quarter, Expanding Commercial Products from 26 to 29 with 14 Customers Fiscal Second Quarter Earnings Call Scheduled for March 17th, 2023 at 8:30 am Eastern Time

Lifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results

Proceeds to be used for debt paydown Proceeds to be used for debt paydown

Lifecore Biomedical Announces Sale of Curation Foods' Avocado Products Business

CHASKA, Minn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), announced today that it received a notice (“Notice”) on January 11, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company failed to timely file its Quarterly Report on Form 10-Q for the quarter ended November 27, 2022 (the “Form 10-Q”) with the Securities and Exchange Commission.

Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report

$38.75 million Private Placement of Series A Convertible Preferred Stock to Support Working Capital and Capital Expenditures While Pursuing Ongoing Divestment Process of non-CDMO Assets

Lifecore Biomedical Raises Capital with Private Placement of Convertible Preferred Stock; Amends Credit Facilities

Hempacco Co Inc

MGP Ingredients

Upexi Inc

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

4 Cheapest Defensive Stocks You Should Think About - Hempacco (NASDAQ:HPCO), Lifecore Biomedical (NASDAQ:LFCR)

MEDNAX

SPAR Group

SGRP, LFCR and MD have been added to the Zacks Rank #5 (Strong Sell) List on December 23, 2022.

New Strong Sell Stocks for December 23rd

Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced the closing of a $5 million private placement (“PIPE”) of its common stock with affiliates of Wynnefield Capital, Inc. (“Wynnefield Capital”), a longtime stockholder of the Company, at $7.97 per share.

News for Lifecore Biomedical Inc Stock (LFCR)